The purpose of this funding opportunity is to support research and development that will characterize the specific and unique considerations relevant to evaluating the bioequivalence (BE) of rectal and vaginal (topical) drug products.
A specific emphasis of this funding opportunity involves the
development of biorelevant performance tests as a component of product characterization-based BE approaches.